<DOC>
	<DOCNO>NCT01777932</DOCNO>
	<brief_summary>This multicenter , single-arm observational study evaluate clinical benefit Avastin ( bevacizumab ) combination paclitaxel first-line treatment patient metastatic breast cancer . Patients metastatic breast cancer start Avastin treatment within 6 month prior study start also eligible . Data collect patient 5 year .</brief_summary>
	<brief_title>AVAREG Study : An Observational Study Avastin ( Bevacizumab ) Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients metastatic breast cancer initiate firstline treatment Avastin combination paclitaxel accord current Hungarian summary Product Characteristics Patients metastatic breast cancer initiate within 6 month start study treatment Avastin accord current Hungarian Summary Product Characteristics Contraindications Avastin accord current Hungarian Summary Product Characteristics : Hypersensitivity active ingredient Avastin excipients Hypersensitivity product produce Chinese hamster cell recombinant humanized antibody Pregnancy Untreated central nervous system metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>